Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 5;11(9):2465.
doi: 10.3390/biomedicines11092465.

Which Comes First, Nonalcoholic Fatty Liver Disease or Arterial Hypertension?

Julia A Golubeva  1 , Anna F Sheptulina  1   2 , Anastasia Yu Elkina  1   3 , Ekaterina O Liusina  1 , Anton R Kiselev  4 , Oxana M Drapkina  1   2
Affiliations
Review

Which Comes First, Nonalcoholic Fatty Liver Disease or Arterial Hypertension?

Julia A Golubeva et al. Biomedicines. .

Abstract

Non-alcoholic fatty liver disease (NAFLD) and arterial hypertension (AH) are widespread noncommunicable diseases in the global population. Since hypertension and NAFLD are diseases associated with metabolic syndrome, they are often comorbid. In fact, many contemporary published studies confirm the association of these diseases with each other, regardless of whether other metabolic factors, such as obesity, dyslipidemia, and type 2 diabetes mellites, are present. This narrative review considers the features of the association between NAFLD and AH, as well as possible pathophysiological mechanisms.

Keywords: hypertension; non-alcoholic fatty liver disease; steatohepatitis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Common pathophysiological links underlining the association between arterial hypertension and non-alcoholic fatty liver disease. See text for explanations. NAFLD = non-alcoholic fatty liver disease; RAAS = renin-angiotensin-aldosterone system; SNS = sympathetic nervous system.
See this image and copyright information in PMC

References

    1. Wu S., Wu F., Ding Y., Hou J., Bi J., Zhang Z. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis. Sci. Rep. 2016;6:33386. doi: 10.1038/srep33386. - DOI - PMC - PubMed
    1. Kuang M., Lu S., Xie Q., Peng N., He S., Yu C., Qiu J., Sheng G., Zou Y. Abdominal obesity phenotypes are associated with the risk of developing non-alcoholic fatty liver disease: Insights from the general population. BMC Gastroenterol. 2022;1:311. doi: 10.1186/s12876-022-02393-9. - DOI - PMC - PubMed
    1. Huh Y., Cho Y.J., Nam G.E. Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease. J. Obes. Metab. Syndr. 2022;1:17–27. doi: 10.7570/jomes22021. - DOI - PMC - PubMed
    1. Zarghamravanbakhsh P., Frenkel M., Poretsky L. Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD) Metabol. Open. 2021;12:100149. doi: 10.1016/j.metop.2021.100149. Erratum in Metabol. Open. 2023, 17, 100231. - DOI - PMC - PubMed
    1. Kasper P., Martin A., Lang S., Kütting F., Goeser T., Demir M., Steffen H.M. NAFLD and cardiovascular diseases: A clinical review. Clin. Res. Cardiol. 2021;7:921–937. doi: 10.1007/s00392-020-01709-7. - DOI - PMC - PubMed

LinkOut - more resources